TABLE 2.

Baseline, week 12, and changes in the outcomes from baseline

	Evogliptin	Linagliptin	Difference [95% CI] or P‐value
	(n = 100)	(n = 104)
HbA1c (%)
Baseline
Mean ± SD	7.55 ± 0.78	7.63 ± 0.78
At week 12
Mean ± SD	6.70 ± 0.73	6.88 ± 0.91
Change from baseline to week 12 (mean ± SD)	−0.85 ± 0.67	−0.75 ± 0.87	−0.10 [−0.32, 0.11]
P‐value for mean difference from baseline at week 12	<.0001 a	<.0001 a
HbA1c response rate	n (%)	n (%)
<7.0%	68 (68.0)	7 0(67.3)	1.0000 c
≥7.0%	32 (32.0)	34 (32.7)
<6.5%	44 (44.0)	38 (36.5)	.3182 c
≥6.5%	56 (56.0)	66 (63.5)
Fasting plasma glucose (mg/mL)
Baseline
Mean ± SD	144.1 ± 24.7	151.1 ± 26.9
At week 12
Mean ± SD	131.3 ± 23.0	135.7 ± 33.5
Change from baseline to week 12 (mean ± SD)	−12.8 ± 19.5	−15.4 ± 34.1	.3253 d
P‐value for mean difference from baseline at week 12	<.0001 b	<.0001 a

Abbreviations: CI, confidence interval, SD, standard deviation.

^a P‐values were derived from a Wilcoxon signed‐rank test.

^b P‐values were derived from a paired t‐test.

^c P‐values were derived from a Fisher's exact test.

^d P‐values were derived from a Wilcoxon rank‐sum test.